Results 41 to 50 of about 5,561 (207)
Dimethyltryptamine: hallucinogenic alkaloid on the Central Nervous System
Acta Brasiliensis, 2018 Hallucinogenic plants are widely used in rituals and religious cults. Ayahuasca tea and wine black Jurema, both hallucinogenic beverages, present the alkaloid dimethyltryptamine (DMT) responsible for the hallucinogenic effect due to interaction with ...
Darliane Freire Almeida +2 more
doaj +1 more source
Pharmaceuticals, 2021 Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD ...
Gniewko Więckiewicz +4 more
doaj +1 more source
Novel psychoactive substances of interest for psychiatry [PDF]
, 2015 Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a ...
Corkery, John +3 more
core +1 more source
Alkaloids from Fissistigma latifolium (Dunal) Merr.
Molecules, 2010 A phytochemical study of the bark of Fissistigma latifolium (Annonaceae) yielded a new aporphine alkaloid, (-)-N-methylguattescidine (1), and eight known alkaloids: liriodenine (2), oxoxylopine (3), (-)-asimilobine (4), dimethyltryptamine (5 ...
Asmah Alias +4 more
doaj +1 more source
Natural Product Communications, 2012 This paper reports the qualitative and quantitative analysis (QA) of mixtures of hallucinogens, N,N -dimethyltryptamine (DMT) ( 1 ), 5-methoxy- ( 1a ) and 5-hydroxy- N,N -dimethyltryptamine ( 1b ) in the presence of β-carbolines (indole alkaloids of type
Bojidarka Ivanova, Michael Spiteller
doaj +1 more source
Mismatch negativity generation in the human 5HT agonist and NMDA antagonist model of psychosis [PDF]
, 2008 RATIONALE: Many studies have reported deficits of mismatch negativity (MMN) in schizophrenic patients. Pharmacological challenges with hallucinogens in healthy humans are used as models for psychotic states.
Karsten Heekeren +46 more
core +2 more sources
Exploring new avenues: Psychedelic‐assisted therapy for young people
British Journal of Clinical Pharmacology, EarlyView.Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou +3 more
wiley +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2023 N,N‐dimethyltryptamine (DMT) is a psychedelic substance and is being used as a research tool in investigations of the neurobiology behind the human consciousness using different brain imaging techniques.
Emma Eckernäs +4 more
doaj +1 more source
Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice [PDF]
, 2017 New psychoactive substances (NPS) are a new breed of synthetically produced substances designed to mimic the effects of traditional illegal drugs. Synthetic cannabinoids and synthetic cathinones are the two most common groups, which try to mimic the ...
Barneo-Muñoz, Manuela +5 more
core +2 more sources
Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review
Addiction, EarlyView.Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper +7 more
wiley +1 more source